PSE investigates the correlation between OS and PFS at ESMO 2017
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Final overall survival (OS) data from FLAURA trial - YouTube
Difference in median overall survival (OS) (months) of individual therapies per International Classification of Diseases 10th revision (ICD–10) category. - ppt download
LENVIMA® (lenvatinib) HCP Website | Overall Survival (OS)
Efficacy of KISQALI® (ribociclib) + AI in Premenopausal | HCP
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine
REVEL Trial Overall Survival for | CYRAMZA® (ramucirumab)
VENCLEXTA® (venetoclax tablets) | VIALE-A Trial Overall Survival Data
Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy
![PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/eb56a0ed555af54134d5949c8b856bff15592fe4/3-Figure1-1.png "PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar")
PDF] Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology | Semantic Scholar
Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review | British Journal of Cancer
LENVIMA® (lenvatinib) HCP Website | Overall Survival (OS)
Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 24 Issue 9 (2017)
Overall survival (OS) by circulating tumor DNA (ctDNA) status in patients with post-operative muscle-invasive urothelial carcinoma (MIUC) treated with atezolizumab (atezo): update from IMvigor010 - UROONCO Bladder Cancer
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
Proposal of a Useful Surrogate Endpoint of the Overall Survival in Patients Undergoing Pulmonary Metastasectomy: The Time to Local Therapy Failure | SpringerLink
Surrogate endpoints for overall survival in advanced non‑small‑cell lung cancer patients with mutations of the epidermal growth factor receptor gene
Kaplan Meier curve showing the overall survival (OS) of the patient... | Download Scientific Diagram
The overall survival (OS) and progression-free survival (PFS) of patients with tumors involving the subventricular zone (SVZ).
1. Why is Overall Survival (OS), in months, | Chegg.com
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative | BMC Pulmonary Medicine | Full
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. - Abstract - Europe PMC
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma - ScienceDirect
